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Available online 19 July 2016Magnetic drug targeting has been proposed asmeans of concentrating therapeutic agents at a target site and the
success of this approach has been demonstrated in a number of studies. However, the behavior of magnetic car-
riers in blood vessels and tumor microcirculation still remains unclear. In this work, we utilized polymeric mag-
netic nanocapsules (m-NCs) for magnetic targeting in tumors and dynamically visualized them within blood
vessels and tumor tissues before, during and after magnetic ﬁeld exposure using ﬁbered confocal ﬂuorescence
microscopy (FCFM). Our results suggested that the distribution of m-NCswithin tumor vasculature changed dra-
matically, but in a reversibleway, upon application and removal of amagnetic ﬁeld. Them-NCswere concentrat-
ed and stayed as clusters near a blood vessel wall when tumors were exposed to a magnetic ﬁeld but without
rupturing the blood vessel. The obtained FCFM images provided in vivo in situ microvascular observations of
m-NCs upon magnetic targeting with high spatial resolution but minimally invasive surgical procedures. This
proof-of-concept descriptive study in mice is envisaged to track and quantify nanoparticles in vivo in a non-
invasive manner at microscopic resolution.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Nanomedicine1. Introduction
Magnetic drug targeting has been shown to be a promising method
of concentrating therapeutic agents at a target site, and allowing higher
drug doses to be administered while still being tolerated by patients
[1–3]. A number of studies have demonstrated that magnetic nanopar-
ticles (MNPs) can be magnetically targeted to tumor sites and the
targeting effect has been assessed by various techniques, including opti-
cal imaging, magnetic resonance imaging (MRI) and histology studies
(Prussian blue staining) [4–11]. These studies have suggested that a
higher concentration of magnetic therapeutic agents can be achieved
upon the application of an external magnetic ﬁeld. However, the mag-
netic behaviors of MNPs in blood vessels and tumor microcirculation
have not been investigated. The above mentioned imaging methods
cannot offer sufﬁcient resolution to show how MNPs travel through
blood vessels and accumulate in tumors, whereas histological studies
can only provide ex vivo information at post-mortem in a non-
dynamic way. Some studies have been carried out using ex vivo artery
models or mathematical simulation to characterize theMNPs behaviors
in blood vessels and/or surrounding tissues, but no in vivo studies have
been performed so far [12–15].mal).
. This is an open access article underHere we visualized the magnetic capture of magnetic polymeric
nanocapsules (m-NCs) within blood vessels and tumor tissues in real-
time in vivo before, during and after magnetic ﬁeld exposure. The mag-
netic targeting efﬁcacy of m-NCs was ﬁrstly quantiﬁed by gamma
counting and this was further conﬁrmed by direct imaging of the mag-
netic targeting process in blood vessel on the microscopic scale. This
proof-of-concept descriptive study in mice is envisaged to track and
quantify nanoparticles in vivo in a non-invasive manner with micro-
scopic resolution.
2. Materials and methods
2.1. Materials
‘Ferroﬂuid’ magnetic oil (oleic acid-coated superparamagnetic iron
oxide nanoparticles (SPIONs) with diameter of 10 nm, suspended in
kerosene at 1017 particles per mL) was purchased from Magnacol Ltd.
(UK). Soybean lecithin (Epikuron 140 V) was a kind gift from
Cargill Pharmaceuticals (USA). Polyoxyethylene-bis-amine (NH2-
PEG3.5 kDa-NH2) was purchased from JENKEM (USA). D/L-lactide/
glycolide copolymer 75/25 (PLGA18 kDa-COOH) was purchased from
Purac Biomaterials (theNetherlands). Tween®80, nitric acid, methanol,
dimethylsulphoxide (DMSO) and dichloromethanewere obtained from
Fisher Scientiﬁc Ltd. (UK). Fluorescein isothiocyanate–dextran (FITC-
Dextran, average molecular weight 2000 kDa), sodium chloride,
diethylene triamine pentaacetic acid (DTPA), castor oil,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Sephadex® G-75 were purchased from Sigma Aldrich (UK). 1,1-
dioctadecyltetramethyl indotricarbocyanine Iodide (DiR) was obtained
from Cambridge Bioscience (UK). Advanced RPMI-1640 media,
penicillin-streptomycin 100×, 0.25% Trypsin-EDTA with phenol red,
Glutamax™ supplement, phosphate buffered saline PBS (10×, pH 7.4)
and phosphate buffered saline PBS (1×, pH 7.4) were obtained from
Gibco, Invitrogen (UK). Fetal bovine serum (FBS) was obtained from
First-Link Ltd. (UK). Pentobarbital sodium (Euthatal®) was obtained
from Merial (UK). PD-10 desalting column was obtained from GE
Healthcare Life Sciences (UK).2.2. Preparation and characterization of m-NCs and m-NC-DiR
The magnetic polymeric nanocapsules (m-NCs) were prepared by
single emulsiﬁcation/solvent evaporation method [1]. PLGA18 kDa-
PEG3.5 kDa-NH2 and PLGA18 kDa-PEG3.5 kDa-DTPAwere synthesized as de-
scribed in our previous work [16,17]. Brieﬂy, PLGA18 kDa-PEG3.5 kDa-NH2
(12.5mg, 10%w/wPLGA18 kDa-PEG3.5 kDa-DTPAwas incorporated form-
NCs to be used for radiolabeling), castor oil (75 mg), soybean lecithin
(25 mg) and increasing amounts of SPIONs (0, 0.5, 2.5 or 10 mg) were
dissolved in 2.5 mL dichloromethane. DiR was incorporated into m-
NCs formulation at 0.5% w/w DiR/castor oil for ﬁbered confocal ﬂuores-
cence microscopic (FCFM) imaging. The organic phase was poured into
an aqueous phase (5 mL) containing Tween® 80 (20 mg) as a hydro-
philic surfactant. The resultant dispersion was emulsiﬁed by ultra-
sonication using a probe sonicator (Soniprep 150, UK) at 15 μ amplitude
for 180 s in an ice bath. Organic solvents were then evaporated in a
chemical fume hood for 20 min. The ﬁnal volume of the m-NC suspen-
sion was adjusted to 5 mL. The obtainedm-NC suspension was concen-
trated using a rotary evaporator (Buchi, Switzerland) by 10 (FCFM
imaging) or 20 times (gamma counting), yielding 25 and 50 mg/ml of
polymer, respectively.2.3. Size and zeta potential measurements
The hydrodynamic size (Z-Average), polydispersity index (PDI) and
zeta potential of NCs and m-NCs were determined by NanoZS (Malvern
Instrument, UK) at 25 °C using disposable square polystyrene cuvettes
(for size and PDI) or disposable capillary cells (for zeta potential)
(Malvern Instrument, UK). The Z-Average diameter and polydispersity
index were measured in water and presented as the average value of
three measurements, with 15 runs within each measurement. The
zeta potential was alsomeasured in water and presented as the average
value of three measurements, with 20–25 runs within each measure-
ment. The mean and standard deviation (SD) of size and zeta potential
were calculated for each sample.2.4. Determination of SPION encapsulation efﬁciency in m-NCs
m-NCs were prepared with increasing loadings of SPIONs (0, 0.38,
1.84 and 7.02% w/w SPION/NC) and puriﬁed by size exclusion chroma-
tography (Sephadex®G-75 column, size exclusion chromatography)
to remove any un-encapsulated SPIONs. The Fe content was deter-
mined by inductively couple plasma mass spectrometry (ICP-MS,
Perkin Elmer SCIEX ICP mass spectrometer, ELAN DRC 6100, USA).
For ICP-MS measurements, Fe standards (Leeman Labs Inc., USA)
were prepared in 20% nitric acid to obtain a standard curve in the
range of 10–10,000 parts per billion with respect to Fe. m-NCs
were digested in 2 mL of nitric acid in Falcon™ 15 mL conical centri-
fuge tubes (Fisher Scientiﬁc, UK) and incubated overnight at 50 °C.
The resulting solution was diluted by 10 times with water before
the measurements.2.5. Determination of DiR encapsulation efﬁciency in m-NCs
The encapsulation efﬁciency of DiR in m-NCs was assessed using a
UV/ﬂuorescence spectrometer (Varian, Cary Eclipse, Australia). Prior
to quantiﬁcation, m-NC-DiR suspensions were puriﬁed by a PD-10
desalting column (size exclusion chromatography) and eluted in PBS
buffer to remove any free DiR. The m-NC suspensions before and after
puriﬁcation were diluted in DMSO (1/19, v/v) to rupture the NC struc-
ture. The excitation/emission wavelengths for the detection of DiR
were 740/785 nm. The encapsulation efﬁciency was expressed as the
percentage of the encapsulated dye to the total amount of DiR added
to the formulation. All measurements were performed in triplicate
and expressed as mean ± SD (n= 3).
2.6. Radio-labelling of m-NCs and serum stability studies
To radio-label them-NCswith indium-111, m-NCswere prepared as
described in the previous section except that PLGA18 kDa-PEG3.5 kDa-
DTPA was included at 10% (w/w) of the total polymer content. The m-
NC suspension (250 μL, 50 mg/mL of polymer) was incubated with
2 M ammonium acetate (one ninth of the reaction volume, pH 5.5), to
which 1 MBq of 111InCl3 (Mallinckrodt, UK) was added for gamma
counting. The reaction was kept at room temperature for 30 min with
intermittent vortexing every 10 min. Upon completion, the radio-
labelling reactionwas quenchedby the addition of 0.1MEDTA chelating
solution (one twentieth of the reaction volume). 111InCl3 alonewas sub-
jected to the same labelling reaction conditions and used as a control.
Them-NC-111Inwas passed through PD-10 columns before injecting
into animals to exchange the ammonium acetate buffer (pH 5.5) with
PBS (pH 7.4) and remove free 111In-EDTA. The m-NCs-111In (~150 μL
per injection dose, 25 mg/mL of polymer) were collected from the col-
umn and spotted on instant thin layer chromatography (iTLC) strips
which were then developed in 0.1 M ammonium acetate containing
50 mM EDTA as a mobile phase. Strips were allowed to dry before
being developed and counted quantitatively using a cyclone phosphor
detector (Packard Biosciences, UK) to ensure no free 111In-EDTApresent
in the injected solution.
2.7. Animal studies and tumor inoculation
All animal experiments were performed in compliance with the UK
Home Ofﬁce (1989) Code of Practice for the Housing and Care of Ani-
mals used in Scientiﬁc Procedures. CT26 murine colon carcinoma cells
(CT26, ATCC®, CRL-2638TM)were cultured in Advanced RPMI (Roswell
Park Memorial Institute) 1640 medium supplemented with 1% L-gluta-
mine, 1% penicillin-streptomycin and 10% fetal bovine serum (FBS), in
5% CO2 and 95% air, at 37 °C. The harvested CT26 cells were suspended
in PBS solution (pH 7.4). A total of 1 × 106 cells in 20 μL were injected
subcutaneously and bifocally at the hind foot of female BALB/c mice
aged 4–6 weeks (Harlan, UK). After inoculation, the tumor volume
was measured on day 8 and then every other day using a digital caliper
and calculated using Eq. (1) [2]
Tumor volume mm3
  ¼ 4=3ð Þ  π A=2ð Þ2  B=2ð Þ ¼ 0:52A2B ð1Þ
where A and B represent thewidth and the length of the tumors, respec-
tively. All experiment were carried out (m-NCs administration) when
the tumor volume reached approximately 500 mm3.
2.8. Magnetic targeting setup in vivo
Disk-shaped nickel-coated neodymium iron boron (Nd2Fe14B) mag-
nets (Magnet Expert Ltd., Tuxford, UK) were used for the in vivomag-
netic drug targeting studies. That was an 8 mm diameter, 5 mm thick,
N42 grade magnet (product code F324), which had a reported ﬁeld
strength of 0.43 Tesla (T) and a reported ‘vertical pull’ parameter (a
Table 1
Physicochemical characterization of PEGylatedm-NCs with different SPION loadings pre-
pared by a single emulsiﬁcation/solvent evaporation method.
Formulation Hydrodynamic
size (nm)[a], [e]
PDI[a], [e] Zeta potential
(mV)[b], [e]
SPION
EE%[c], [e]
Final SPION
loading[d], [e]
NC 1 203 ± 4 0.12 ± 0.01 −45 ± 2 — 0.00
NC 2 212 ± 2 0.17 ± 0.02 −38 ± 1 99 ± 3 0.08 ± 0.01
NC 3 218 ± 4 0.17 ± 0.02 −39 ± 1 99 ± 2 0.38 ± 0.01
NC 4 205 ± 3 0.16 ± 0.01 −36 ± 1 95 ± 3 1.76 ± 0.06
NC 5 214 ± 9 0.19 ± 0.02 −31 ± 1 94 ± 9 6.60 ± 0.63
a Size was measured with dynamic light scattering and measured in deionized water
b Values were obtained with laser Doppler electrophoresis and measured in deionized
water
c Iron content was determined by ICP-MS
d Weight of NCs includes polymer, lecithin, castor oil, SPION and tween 80®. Initial and
ﬁnal loading refers to SPION content before and after size exclusion chromatography.
e Results are expressed as mean ± SD (n = 3)
242 J. Bai et al. / Journal of Controlled Release 244 (2016) 240–246measure of the mass of material that the magnet could lift) of 1.9 kg.
Single magnet was placed non-invasively over the surface of one of
the bifocal tumors immediately after m-NCs administration and
retained using surgical tapes. The contralateral tumorwas used as an in-
ternal negative control where no magnet was applied. The magnet was
then removed at 1 h post-injection of m-NCs.
2.9. Fibered confocal ﬂuorescence microscopic imaging studies
The visualisation of m-NCs in tumor vasculature in vivo upon the ap-
plication of a magnetic ﬁeld was performed using a ﬁbered confocal
ﬂuorescence microscopy (FCFM) imaging system (Cellvizio®, Mauna
Kea Technologies, Paris, France). CT26 tumor-bearing BALB/c mice
were injected via a tail vein with m-NC-DiR with a SPION content of
125 mg/kg and DiR content of 9.4 mg/kg (corresponding to
312.5 mg polymer/kg). FITC-Dextran (MW 2000 kDa, 500 mg/kg,
150 μL) was injected intravenously immediately prior to FCFM imaging
to visualize the microvascular network. A small incision (~0.5 cm) was
made on tumor and muscle to insert the laser probe. The exposed tis-
sues were kept moist with PBS pre-warmed to 37 °C. During the time
of acquisition, mice were placed in the prone position (for tumor and
muscle imaging) or supine position (for liver imaging) and anesthetized
with 1.5% isoﬂurane/98.5% oxygen. Body temperaturewas controlled by
a probe-coupled heatingmat. Images and videoswere acquired using an
S-1500 probewith a penetration depth of 15 μmbelow tissue surface. To
image m-NCs in the tumor vasculature upon exposure to a magnetic
ﬁeld in real-time, a set of magnets (10 disk magnets, 0.43 T, product
code F324, Magnet Expert Ltd., Tuxford, UK) was placed adjacent to
the surgical incision for 10 min. FCFM imaging was performed before,
during and after application of a magnetic ﬁeld. Extravasation of the
m-NCs through blood vessel wall and accumulation over time were
also assessed in tumor (TU+ and TU−), quadriceps femoris muscle
and liver at 1, 4 and 24 h post-injection. All imaging was carried out
using a frame rate of 9 Hz (full FOV), a ﬁeld of view of 618 × 609 μm
and 100% laser power at 488 and 660 nm. Images and videos were ana-
lyzed using Cellvizio® dual viewer (Mauna Kea Technologies, Paris,
France) and videos were reconstructed using ImageJ software. The ﬂuo-
rescence intensity of the signals fromDiR and FITCwas quantiﬁed using
ImageJ software.
2.10. Assessment of blood circulation, organ biodistribution and tumor ac-
cumulation proﬁles of m-NCs by gamma counting
Blood circulation, organ biodistribution and tumor accumulation
proﬁles of m-NC-111In with increasing SPION contents (0, 5, 25 and
125 and 500 mg/kg), referred to as NC 1, NC 2, NC 3, NC 4 and NC 5, re-
spectively, were assessed quantitatively in CT26 tumor-bearing BALB/c
mice using gamma counting. Mice were injected intravenously via tail
vein with ~0.7 MBq m-NC-111In (150 μL in PBS). Magnetic targeting
was applied as described in 2.8. Blood samples (5 μL) were collected
from the tail vein at 10 min, 30 min, 1 h, 4 h and 24 h post-injection.
Liver, spleen, magnetically-targeted tumors (TU+) and non-
magnetically targeted tumors (TU−) were excised and weighed. The
radioactivity was measured by a gamma counter (1280 CompuGamma
Universal Gamma Counter, LKB Wallac, Finland), using the appropriate
energy windows for 111In. Results were expressed as percentage of
injected dose (% ID) in blood or per gram organ or tumor (% ID/g) as
means ± SEM (standard error of the mean) (n= 3).
2.11. Statistical Analysis
The statistical analysis for each experiment is noted in the ﬁgure
caption. The One-way ANONA and Tukey’s multiple comparison test
were performed for the gamma counting studies, including organ
biodistribution, blood circulation and tumor accumulation studies.
Student’s t-test was performed for the FCFM quantiﬁcation studies. Allstatistical tests were performed using IBM SPSS version 20. The signiﬁ-
cance (p-value) was determined. When p-values were 0.05 or less,
differences were considered statistically signiﬁcant.
3. Results and discussion
3.1. Preparation and characterization of magnetic nanocapsules (m-NCs)
We designed a magnetic nanocapsule system (m-NCs) encapsulat-
ing a high amount of superparamagnetic iron oxide nanoparticles
(SPIONs) which enables successful magnetic drug targeting in vivo.
The m-NCs were designed in such a way that they can be imaged with
optical imaging (due to DiR incorporation), MR imaging (due to
SPION) and nuclear imaging (by chelation of radioactive indium-111
(111In) to diethylene triamine pentaacetic acid (DTPA) conjugated to
the polymer). These triple-labeled m-NCs combined with imaging
techniques such as SPECT/CT and FCFM allowed us to examine the
kinetics ofm-NCs accumulation/extravasation inmice organs, including
tumors, on a microscopic scale when an external magnetic ﬁeld was
applied.
PEGylated oil-coredm-NCs were prepared using a single emulsiﬁca-
tion/solvent evaporation method. [16] DiR was encapsulated into
the m-NCs for FCFM imaging. m-NCs of increasing SPION loadings: ca.
0-7% w/w SPION/NC were prepared and named as NC 1-5, respectively,
were prepared. DiR/SPION encapsulation efﬁciency (%EE), hydrody-
namic sizes (200 to 220 nm) and zeta potentials (−30 to −45 mV)
are summarized in Table 1 and Table 2.
3.2. The correlation between m-NC tumor accumulation and SPION injec-
tion dose under passive and magnetic targeting conditions
We ﬁrstly assessed the blood circulation time ofm-NCs with an in-
creasing amount of SPIONs, their uptake in reticuloendothelial system
(RES) organs (e.g. liver and spleen), and the tumor accumulation in
the presence (TU+) or absence (TU-) of amagnetic ﬁeld in a subcutane-
ous CT26 (murine colon carcinoma) tumor model. These m-NCs were
radio-labeled with 111In and their concentrations in blood and tumors
weremeasured by gamma counting. Fig. 1a shows the percentage injec-
tion dose (% ID) of m-NCs accumulated in the tumor (per gram of
tumor) (+/- magnetic ﬁeld), at 24 h post-injection, against increasing
doses of injected SPIONs in m-NCs. The tumor accumulation was not
affected by increasing the SPION injection dose up to 125 mg/kg (NC
4, ca. 2% w/w) in the absence of a magnetic ﬁeld (blue line TU-, r2 =
0.7872, p = 0.1127). On the other hand, a linear regression between %
ID/g and Ln (SPION dose mg/kg) (red line TU+, r2 = 0.9338, p =
0.0337) was observed from NC 1-4 when a magnetic ﬁeld was applied.
The statistical analysis of the linear regression is provided in Table S1.
The good regression between these two parameters indicates the mag-
netic force was able to inﬂuence the tumor uptake and the
Table 2
Physicochemical characterization of PEGylatedDiR encapsulatedNCs andm-NCs prepared
by a single emulsiﬁcation/solvent evaporation method.
Formulation[a] Hydrodynamic size
(nm)[b], [e]
PDI [b], [e] Zeta potential
(mV)[c], [e]
DiR
EE%[d], [e]
NC-DiR 206 ± 5 0.16 ± 0.01 -39 ± 2 99 ± 4
m-NC-DiR 209 ± 2 0.19 ± 0.02 -32 ± 1 95 ± 5
a Formulations were prepared based on NC 4
b Size was measured with dynamic light scattering and measured in deionized water
c Values were obtained with laser Doppler electrophoresis and measured in deionized
water
d Values were determined by ﬂuorescence spectroscopy
e Results are expressed as mean ± SD (n = 3)
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rithm of the injected SPION dose. A signiﬁcant reduction in tumor up-
take was observed when mice were injected with NC 5 with the
highest SPION content (ca. 7% w/w, 500 mg/kg). Fig. 1b and c show
their blood concentration over time and %ID/g in liver and spleen at
24 h. The high uptake of NC 5 in RES organs correspondedwell to the re-
duced blood circulation timewhichmay lead to its lowered tumor accu-
mulation [18].
3.3. Live ﬁbered confocal ﬂuorescence microscopic imaging of m-NCs in
tumor blood vessel under the inﬂuence of a magnetic ﬁeld
The investigation of the effect of magnetic forces on m-NC accumu-
lation kinetics in the tumor vasculature is limited by the imaging resolu-
tion and invasiveness. As a result, to visualize it dynamically on a
microscopic vascular level, a ﬁbered confocal ﬂuorescence microscopy
system (FCFM, Cellvizio®, Mauna Kea Technology, Paris, France) wasy = 0.6005x + 2.5457
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Fig. 1. Biodistribution studies ofm-NC-111In in CT26 tumor-bearing BALB/c mice under the inﬂu
SPION content of 0-500mg/kg. Blood sampleswere collected at speciﬁed time points and organs
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One-way ANOVA was performed using IBM SPSS version 20 followed by Tukey’s multiple comused in this study. Non-magnetic NCs (used as a negative control) and
m-NCswere ﬂuorescently labeled with DiR as an optical probe. Fluores-
cein isothiocyanate–dextran (FITC-Dextran), used as a vascular contrast
agent, remained in the blood vessels and no leakage up to 1 h has been
reported. Mice were inoculated bi-focally with subcutaneous tumors.
The imaging laser probe was inserted into the tumors via a small
incision and tissues were keptmoist throughout the experiment. To dy-
namically image the travelling of the m-NCs in blood vessels, the FCFM
was performed before, during and after the magnetic exposure. The
imaging protocol is schematically presented in Fig. 2a.
Prior to application of a magnetic ﬁeld, DiR-labeled non-magnetic
NCs were observed homogenously distributed in blood vessels
(Fig. 2b, left panel; Supplementary Movie 1a–c). The application of a
magnetic ﬁeld did not cause any changes in the distribution of non-
magnetic NCs within the blood vessels. m-NCs, on the other hand, be-
haved differently when a set of magnets was applied in close proximity
to the vessels. DiR labeled m-NCs started to magnetize, and those mag-
netized sufﬁciently appeared as clusters and enriched near the blood
vessel wall (Fig. 2b, right panel; Supplementary Movie 1d–f). The m-
NC aggregation was reversible upon removal of the magnetic ﬁeld due
to the superparamagnetism of m-NCs [1,2,19]. More importantly, the
blood vessels appeared intact with no observation of vessel leakage of
FITC-Dextran induced by the application of the magnetic ﬁeld, suggest-
ing no vascular damage per se. The enrichment of m-NCs within the
tumor microvasculature or further enhanced retention in blood vessels
would raise the probability of extravasation into the tumor interstitium
and thereby increase tumor uptake.
The m-NC distribution in both TU− and TU+ over time was also
studied using FCFM. The multiple imaging schedule is shown in
Fig. 3. m-NCs were injected at 0 h and a magnetic ﬁeld was then ap-
plied to one tumor for 1 h. Multiple imaging was performed at 1, 4spleen
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Fig. 2.Real time ﬁbered confocal ﬂuorescencemicroscopic (FCFM) images ofmagnetic targeting in tumor tissues. Fluorescently labeled non-magnetic NC (NC-DiR) ormagnetic NC (m-NC-
DiR) (red signals) were injected intravenously into CT26 tumor-bearing BALB/c mice and imaged with FCFM using FITC-Dextran (green) as the vascular contrast agent. (a) Schematic
illustration of the live FCFM imaging in tumor blood vessels with an external magnetic ﬁeld (MF) applied at the external part of tumor without direct contact. (b) Representative
single frame of live FCFM imaging of NC-DiR and m-NC-DiR in tumors before, during and after the application of the magnets. Dashed circle shows the magnetizedm-NC-DiR, and not
NC-DiR is concentrated in the blood vessels upon the application of a magnetic ﬁeld. All images were acquired using the Cellvizio® dual band imaging system.
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networks and non-vascularized areas of necrosis [20–22]. FCFM im-
aging was performed focusing on the highly vascularized regions.Fig. 3. Experimental timeline of ﬁbered confocal ﬂuorescence microscopic (FCFM) imaging o
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CT26 tumor-bearing BALB/cmice and imagedwith FCFMusing FITC-Dextran as the vascular contrast agent. Amagnetic ﬁeldwas taped at one of tumor surface (TU+) for 1 h and removed
afterwards. The contralateral tumor (TU-)wasused as a control. (a) Representative single frameFCFM images ofm-NCs in TU- and TU+at 1, 4 and 24h post-injection. (b)Quantiﬁcation of
the ﬂuorescence intensity ofm-NC-DiR in TU- and TU+. Values are expressed as the ratio of ﬂuorescence intensity from DiR and FITC as mean ± SD (n=3). Paired student t-test was
performed using IBM SPSS version 20 (*p b 0.05).
245J. Bai et al. / Journal of Controlled Release 244 (2016) 240–246DiR signals became more diffuse and spread out throughout the
tumor interstitium at 24 h. The overall ﬂuorescence intensity of
signals from m-NC-DiR and FITC-Dextran in TU+ and TU- was
quantiﬁed. The intensity ratios of DiR/FITC were used to compare
the accumulation of m-NC-DiR in TU+ and TU and the obtained
results are shown in Fig. 4b. Interestingly, higher ﬂuorescence inten-
sity ofm-NC-DiR (higher DiR/FITC ratio) was seen in TU+ compared
to TU- at 24 h, suggesting enhanced tumor accumulation upon
magnetic targeting, consistent with our previously published work
[16].3.4. Real-time ﬁbered confocal ﬂuorescence microscopic imaging of m-NCs
extravasation in healthy tissues
The extravasation of m-NCs were also assessed in healthy tissues to
validate the usefulness for real-time nanoparticle imaging. Muscle and
liver which exhibit distinct vascular characteristics were used as exam-
ples [23]. Fig. 5 (left panel) shows muscle blood vessels. No DiR signal
was visible in the blood vessels of muscle tissues at 24 h, in contrary
to the 1 h time point where m-NCs were seen in the vasculature. This
is consistent with m-NC distribution data, where no m-NC retention
was seen in muscle at 24 h, due to the continuous capillaries and com-
plete basementmembrane [16,24,25]. It was also conﬁrmed that DiR la-
belling was conﬁned to the m-NCs and the dye did not translocate to
cellular membrane. In contrast, a number of m-NCs leaked out of the
liver sinusoids and accumulated in non-vascular liver tissues at 24 h
(Fig. 5, right panel), consistent with gradual liver accumulation over
time described in our previously published work [16]. This was notsurprising as the liver vasculature has an incomplete basement mem-
brane and transcytoplasmic openings [25].
It is conceivable from experimental physics and prior knowledge
that magnetic nanoparticles (MNPs) can be attracted by the magnetic
forces in tumor blood vessel and be concentrated to the tumor tissue.
A number of studies indeed have demonstrated that MNPs could be
concentrated in the tumor under the inﬂuence of a magnetic ﬁeld by
MRI [5,11]. However, MRI cannot provide sufﬁcient resolution to
image the MNP in tumor vasculature. Whether or not the magnetic
forces acting on individual m-NC is strong enough to overcome blood
ﬂow has not been addressed. A direct visualisation in a time-course
study is required.
The FCFM provides real-time in vivomicrovascular observations and
in situ high spatial resolution imaging (up to 1.4 μm) at vascular level. It
also represents a signiﬁcant advantage over traditional intra-vital mi-
croscopic imaging (IVM)whichusually requires invasive surgical proce-
dures and is limited by the availability of animal models that bear
visually accessible tumors in a dorsal skinfold chamber. FCFM enables
micro-invasiveness and requires only a small incision at the imaging
site. Small openings can be sutured if the animals are required to be
kept for long-term studies.
4. Conclusion
A number of studies have exploredmagnetic targeting in drug deliv-
ery. However, this is theﬁrst report of real-time live imaging ofmagnet-
ic targeting in tumor vasculature on the microscopic scale. The novel
application of FCFM described in this study offers direct visualisation
of m-NCs within blood vessels and in tumor tissues before, during and
100 µm
Fig. 5. Real-time ﬁbered confocal ﬂuorescencemicroscopic (FCFM) images of m-NCs inmuscle and liver.m-NC-DiRwere injected intravenously into CT26 tumor-bearing BALB/cmice and
imagedwith FCFMusing FITC-Dextran as the vascular contrast agent. Representative single frame FCFM images ofm-NC inmuscle and liver tissues at 1, 4 and 24 h post-injectionwith the
application of a magnetic ﬁeld at the tumor. All images were acquired using the Cellvizio® dual band imaging system. Scale bar is 50 um.
246 J. Bai et al. / Journal of Controlled Release 244 (2016) 240–246after magnetic ﬁeld exposure in a real-time manner, with high resolu-
tion and minimal surgical intervention. Our results suggested that the
distribution of m-NCs within tumor vasculature changed dramatically,
but in a reversible way, upon application and removal of a magnetic
ﬁeld. The m-NCs were concentrated and stayed as clusters near a
blood vessel wall when tumors were exposed to a magnetic ﬁeld but
without rupturing the blood vessel. This work bridges the gap between
previous ﬁndings of enhanced tumor uptake with magnetic targeting
and the nanocarrier behavior at the blood-tumor vasculature-tumor tis-
sue interface, thanks to the high resolution characteristics of this imag-
ing modality. This proof-of-concept descriptive study in mice is
envisaged to track and quantify nanoparticles in vivo in a non-invasive
manner with microscopic resolution.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2016.07.026.
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